Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Infectious Diseases

Topics

Medicine

Immunology

Pathology

Internal Medicine

Pediatrics

Show all topics

DOI

10.1016/s1473-3099(21)00127-4

License

other-oa